Sarepta Therapeutics

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Sarepta reports robust earnings, poised for gene therapy milestone

Sarepta Therapeutics delivered strong financial performance in Q4 2022, driven by revenue growth and positive market reception of its RNA-based PMO therapies.
While facing challenges in managing expenses and navigating regulatory uncertainties, the company is strategically positioned to capitalize on growth opportunities in gene therapy and market expansion.
By focusing on innovation, operational readiness, and market access, Sarepta aims to secure a leading position in Duchenne muscular dystrophy treatment and drive sustainable revenue growth.

Sarepta Therapeutics exceeds Q1 revenue expectations, poised for growth

Sarepta Therapeutics delivered strong financial results in Q1 2023, exceeding expectations and showcasing market confidence in their growth trajectory.
The company's proactive approach to patient access, payer engagement, and therapy development highlights their commitment to addressing unmet medical needs and advancing innovative treatments.
While facing pricing challenges and regulatory decisions, Sarepta's focus on research, partnerships, and therapy expansion presents opportunities for sustained growth and impact.
With a robust pipeline, positive payer discussions, and ongoing studies, Sarepta is poised to make a significant difference in treating rare diseases and improving patient outcomes.

Sarepta Therapeutics excels in Q2 with ELEVIDYS approval and patient-focused strategies

Sarepta Therapeutics demonstrated strong performance in Q2 2023 with positive revenue growth and progress in clinical studies and commercial activities.
Despite challenges in administrative processes and label expansion, the company's focus on patient care and operational efficiency remains a key strength.
Opportunities lie in broadening therapy access, addressing limitations, and streamlining patient access post label expansion for enhanced market reach and treatment efficiency.

Sarepta Therapeutics excels in Q3 earnings, eyes label expansion

Sarepta Therapeutics delivered robust financial performance in Q3 2023, driven by the success of ELEVIDYS and PMOs. Despite challenges in regulatory processes and market competition, the company's strategic focus on label expansion and patient access presents significant growth opportunities.

Sarepta Therapeutics reports robust Q4 earnings and targets pipeline expansion

Sarepta Therapeutics delivered strong financial results in Q4 2023, showcasing revenue growth and profitability. Despite facing challenges such as potential margin declines and clarity issues, the company is well-positioned to capitalize on opportunities for pipeline advancement and expansion.

Sarepta Therapeutics excels in Q1 earnings, eyes label expansions

Sarepta Therapeutics delivered strong financial performance in Q1 2024, driven by robust revenue growth and steady demand for key products like ELEVIDYS.
The company's strategic focus on label expansions and innovative R&D efforts positions it well for future success in addressing unmet medical needs and driving market expansion.
While facing challenges in patient demographics and operational readiness, Sarepta remains well-capitalized and poised to capitalize on upcoming opportunities for growth and market leadership.

Sarepta Therapeutics reports robust Q2 revenue and eyes therapy expansion

Sarepta Therapeutics is experiencing strong revenue growth driven by ELEVIDYS, with a focus on patient outcomes and manufacturing capacity. Challenges include addressing bottlenecks and patient prioritization, while opportunities exist in therapy development and market expansion.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

MeiraGTx Holdings plc

uniQure

Solid Biosciences

Voyager Therapeutics

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

CAMBRIDGE, Mass., Sept. 14, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the World Muscle Society 2021 Virtual Congress (WMS 2021), taking place Sept. 20-24, 2021. This year's presentations at WMS 2021 highlight scientific leadership and innovation from across Sarepta's deep, multi-platform portfolio and reflect the Company's continued commitment advancing life-changing therapies to those with rare genetic diseases.

Sarepta Therapeutics to Showcase Data from its Gene Therapy and RNA Platforms at World Muscle Society 2021 Virtual Congress

Morgan Stanley

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Morgan Stanley 19th Annual Global Healthcare Conference (Transcript)

We believe that ​Sarepta Therapeutics stock, a biotech company focused on the discovery and development of RNA-targeted therapeutics and gene therapy for the treatment of rare diseases, is a good buying opportunity at the present time. SRPT stock trades under $80 levels currently and it is.

How Does Sarepta's Stock Performance In The Current Crisis Compare With That In 2008?

Ultragenyx Pharmaceutical

A drug maker, two insurers, and a medical-device company pass our screen of healthcare concerns with high analysts ratings and upside potential.

4 Underpriced Healthcare Stocks That Wall Street Adores

AbCellera Biologics

ACADIA Pharma

Amicus Therapeutics

TG Therapeutics

One particular group of stocks is overrepresented among the exchange's biggest losers this year. That's an important detail.

Is It Time to Buy 5 of the Nasdaq's Worst-Performing Stocks of 2021?

Strong demand for Sarepta's (SRPT) DMD drugs boosts its top line in Q2. The company also raises revenues guidance for the year.

Sarepta (SRPT) Q2 Earnings Beat, 2021 Sales View Raised

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram on Q2 2021 Results - Earnings Call Transcript

–  Limb-girdle muscular dystrophy type 2A is the most common form of LGMD, accounting for a third of LGMD diagnoses

Sarepta Therapeutics Executes Licensing Agreement for Gene Therapy Program from Nationwide Children's Hospital to Treat Limb-Girdle Muscular Dystrophy Type 2A

Sarepta Therapeutics (NASDAQ:SRPT) will be releasing its next round of earnings this Wednesday, August 04. For all of the relevant information, here is your guide for Wednesday's Q2 earnings announcement.

Sarepta Therapeutics's Earnings: A Preview

Sarepta Therapeutics (SRPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Should You Buy?

CAMBRIDGE, Mass., July 28, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2021 financial results after the Nasdaq Global Market closes on Wednesday, August 4, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its second quarter 2021 financial results and to provide a corporate update.

Sarepta Therapeutics to Announce Second Quarter 2021 Financial Results and Recent Corporate Developments on August 4, 2021

Neurocrine Biosciences

Vertex, Inc.

Our theme of Out Of Favor Health Care Stocks includes healthcare and pharma names that are seeing a disconnect between their financial performance and stock price returns. Specifically, the theme filters for healthcare companies that have grown revenue by at least 50% over the last three years.

Sarepta, Vertex, Neurocrine: There's Deep Value In These Beaten Down Healthcare Stocks

Amazon

Skillz

Teladoc

Analysts are expecting big things from these fast-paced companies over the next 12 months.

5 High-Growth Stocks With 62% to 144% Upside, According to Wall Street

Bank of America

Sarepta Therapeutics, Inc. (SRPT) CEO Doug Ingram Presents at Bank of America Securities 2021 Napa BioPharma Virtual Conference (Transcript)

Goldman Sachs

Sarepta Therapeutics, Inc. (SRPT) CEO Douglas Ingram Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock?

Why Is Sarepta Therapeutics (SRPT) Down 1.1% Since Last Earnings Report?

GameStop

Tesla

Institutional investors and hedge funds wanted nothing to do with these widely owned stocks in the first quarter.

3 Popular Stocks Money Managers Couldn't Stop Selling in Q1

Sarepta's (SRPT) lead gene therapy candidate, SRP-9001, demonstrates robust improvement in expression of micro-dystrophin protein in DMD patients after 12 weeks of treatment.

Sarepta (SRPT) Rises on Robust DMD Gene Therapy Study Data

Sarepta Therapeutics (SRPT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Sarepta Therapeutics (SRPT) Moves 8.4% Higher: Will This Strength Last?

Shares of Sarepta Therapeutics (SRPT) closed higher after announcing positive data for its Duchenne Muscular Dystrophy (DMD) drug.

Why Sarepta Therapeutics (SRPT) Stock Soared on Tuesday

Sarepta Therapeutics, Inc. (SRPT) Presents at RBC Capital Markets Global Healthcare Broker Conference Call - (Transcript)

Sarepta Therapeutics Inc (NASDAQ: SRPT) has announced positive 12-week results from the first 11 participants enrolled in open-label study 9001-103 ENDEAVOR being conducted in partnership with Roche Holdings AG's (OTC: RHHBY). Results demonstrated robust expression of micro-dystrophin and no new safety signals from prior studies.

Sarepta's Stock Trading Higher As Duchenne Muscular Dystrophy Gene Therapy Shows Promise In Open-Label Study

Shares of Sarepta Therapeutics Inc. gained 11.3% in trading on Tuesday after the company shared positive data from a mid-stage, open-label clinical trial for its experimental Duchenne muscular dystrophy treatment. The data comes from the first 11 enrolled participants in a study of 20 participants who are between the ages of 4 and 7 years old.

Sarepta's stock is up 11% on positive data from clinical trial for Duchenne treatment

CAMBRIDGE, Mass., May 18, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced positive 12-week expression and safety results from the first 11 participants enrolled in Study SRP-9001-103, an open-label study known as ENDEAVOR being conducted in partnership with Roche. In results from the first clinical study using commercially representative material, SRP-9001 (rAAVrh74.MHCK7.micro-dystrophin) demonstrated robust expression of micro-dystrophin and no new safety signals from prior studies, supporting its potentially differentiated profile for the treatment of Duchenne muscular dystrophy. SRP-9001 is an investigational gene transfer therapy intended to deliver its micro-dystrophin-encoding gene to muscle tissue for the targeted production of the micro-dystrophin protein.

Sarepta Therapeutics' Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy, SRP-9001, Demonstrates Robust Expression and Consistent Safety Profile Using Sarepta's Commercial Process Material

News for Sarepta Therapeutics Stock (SRPT)